When multiple myeloma relapses

RESPOND with a treatment with a tolerable safety profile

Kd adverse events

In the ENDEAVOR trial there was a longer treatment duration in the Kd arm vs the Rd arm (40 vs 27 weeks, respectively).1
AE-related discontinuation rates* were similar between Kd and Vd arms.1

Adapted from Dimopoulos et al.1

Refer to Summary of Product Characteristics and Prescribing Information for comprehensive safety information

Frequency of AEs may vary between studies. Refer to SmPC for selected AEs reported in clinical studies.2 *In the intention-to-treat population: Kd (n=464) and Vd (n=465).

Please read the SmPC for full comprehensive safety information

References

  1. Dimopoulos MA et al. Lancet Oncol 2016;17:27–38.
  2. Kyprolis® (carfilzomib) Summary of Product Characteristics; 2016.

Terms of Use

The information contained in this site is for European healthcare professionals only.

Kyprolis